View Cart  

Advisory Panel Vote on Pfizer’s Prevnar-13 Could Spell Trouble for Merck Vaccine

A A
Pfizer is positioned to take a big bite out of Merck’s share of the adult pneumonia vaccine market following an FDA advisory panel’s approval recommendation for Prevnar-13.

To View This Article:

Login

Subscribe To Drug Industry Daily